CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
نویسندگان
چکیده
منابع مشابه
P 133: Neuroinflammation in Alzheimer ’s Disease
Alzheimer’s disease (AD) is a neurodegenerative disorder and the most common form of dementia. Almost 47 million people suffer from dementia worldwide. AD accounts for approximately 60%–80% of all dementia cases. Three major pathologies characterize the disease: senile plaques, neurofibrillary tangles and inflammation. We review the literature on events contributing to the inflammat...
متن کاملSelected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease
OBJECTIVE To investigate CSF biomarkers of neuroinflammation and neurodegeneration in Huntington disease (HD) gene-expansion carriers compared to controls and to investigate these biomarkers in association with clinical HD rating scales and disease burden score. METHODS We collected CSF from 32 premanifest and 48 manifest HD gene-expansion carriers and 24 gene-expansion negative at-risk contr...
متن کاملAge and diagnostic performance of Alzheimer disease CSF biomarkers.
OBJECTIVES Core CSF changes in Alzheimer disease (AD) are decreased amyloid β(1-42), increased total tau, and increased phospho-tau, probably indicating amyloid plaque accumulation, axonal degeneration, and tangle pathology, respectively. These biomarkers identify AD already at the predementia stage, but their diagnostic performance might be affected by age-dependent increase of AD-type brain p...
متن کاملCSF Biomarkers for Alzheimer Disease Diagnosis: Recent and Future Perspectives
Until recently, Alzheimer’s disease (AD) was diagnosed clinically by excluding other conditions and pathologies, at best resulting in a diagnosis of probable AD [1]. Compared to autopsy-confirmed diagnoses, only 68% of the dementia patients were correctly diagnosed using these clinical diagnostic criteria for AD [2,3]. Moreover, a clinical diagnosis of probable AD was confined to the dementia s...
متن کاملDetailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
OBJECTIVE To compare the diagnostic accuracy of CSF biomarkers and amyloid PET for diagnosing early-stage Alzheimer disease (AD). METHODS From the prospective, longitudinal BioFINDER study, we included 122 healthy elderly and 34 patients with mild cognitive impairment who developed AD dementia within 3 years (MCI-AD). β-Amyloid (Aβ) deposition in 9 brain regions was examined with [18F]-flutem...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurology
سال: 2018
ISSN: 0028-3878,1526-632X
DOI: 10.1212/wnl.0000000000006082